Private Equity Holding AG or PEH announced that a portfolio company Enanta Pharmaceuticals has entered into a strategic collaboration with Novartis AG (NVS) for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, from its NS5A hepatitis C virus or HCV inhibitor program.
PEH is a minority shareholder and invested in Enanta in 1999 as part of the original shareholder syndicate.
For comments and feedback: editorial@rttnews.com